Lupin Limited has informed the Exchange about U.S. FDA has concluded an inspection at our manufacturing facility at Ankleshwar, India.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The U.S. FDA inspected Lupin's Ankleshwar manufacturing facility in India from March 2 to March 7, 2026. The inspection concluded with the issuance of a Form-483 carrying two observations. The company has stated it will respond to the FDA within the required timeframe and address the observations. Lupin reaffirmed its commitment to Current Good Manufacturing Practice (CGMP) standards across all facilities. This is a routine regulatory disclosure under SEBI Listing Regulations and does not indicate any warning letter, import alert, or enforcement action.
A Form-483 with only two observations is generally considered minor and is common in routine FDA inspections; it is unlikely to materially affect the stock price. Investors should monitor the company's response to the FDA to ensure the observations are resolved without escalation.